NEW YORK (GenomeWeb) – 23andMe has raised $79.1 million of a targeted $150 million in a private financing, according to a document filed with the US Securities and Exchange Commission.
In a filing with the SEC on July 2, 23andMe said it is seeking to raise $150 million through the sale of Series E Preferred Stock. It said that it made the first sale of stock in the round on June 18.
The firm said that 15 investors have participated in the round so far, but it did not disclose the names of those investors.
In March, the firm launched a therapeutics group headed by former Genentech executive Richard Scheller. And earlier this year, it received clearance from the US Food and Drug Administration to market its first health-related test, for Bloom syndrome, directly to consumers.